Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients

References

• Wen Y, Wang X, Wang B, Yuan Z. Vaccine therapies for chronic hepatitis B: can we go further? Frontiers Med 2014; 8:17-23; https://doi.org/10.1007/s11684-014-0313-7
   PubMed Web of Science ®Google Scholar
• Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011; 54:1286-96; https://doi.org/10.1016/j.jhep.2010.12.031
   PubMed Web of Science ®Google Scholar
• Akbar SM, Furukawa S, Horiike N, Abe M, Hiasa Y, Onji M. Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B. J Viral Hepatitis 2011; 18:408-14; PMID:20487261; https://doi.org/10.1111/j.1365-2893.2010.01320.x
   PubMed Web of Science ®Google Scholar
• Luo J, Li J, Chen RL, Nie L, Huang J, Liu ZW, Luo L, Yan XJ. Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers. Vaccine 2010; 28:2497-504; PMID:20117267; https://doi.org/10.1016/j.vaccine.2010.01.038
   PubMed Web of Science ®Google Scholar
• Chisari FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000; 156:1117-32; PMID:10751335; https://doi.org/10.1016/S0002-9440(10)64980-2
   PubMed Web of Science ®Google Scholar
• Michel ML, Pol S, Brechot C, Tiollais P. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 2001; 19:2395-9; PMID:11257367; https://doi.org/10.1016/S0264-410X(00)00461-8
   PubMed Web of Science ®Google Scholar
• Michel ML, Loirat D. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B. Intervirology 2001; 44:78-87; PMID:11509869; https://doi.org/10.1159/000050035
   PubMed Web of Science ®Google Scholar
• Voehringer D, Blaser C, Grawitz AB, Chisari FV, Buerki K, Pircher H. Break of T cell ignorance to a viral antigen in the liver induces hepatitis. J Immunol 2000; 165:2415-22; https://doi.org/10.4049/jimmunol.165.5.2415
   PubMed Web of Science ®Google Scholar
• Chen S, Akbar SM, Abe M, Hiasa Y, Onji M. Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin Exp Immunol 2011; 166:134-42; PMID:21762128; https://doi.org/10.1111/j.1365-2249.2011.04445.x
   PubMed Web of Science ®Google Scholar
• Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa JP, Dittmer U, Yang D, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009; 49:1132-40; PMID:19140219; https://doi.org/10.1002/hep.22751
   PubMed Web of Science ®Google Scholar
• Ye B, Liu X, Li X, Kong H, Tian L, Chen Y. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis 2015; 6:e1694; https://doi.org/10.1038/cddis.2015.42
   PubMed Web of Science ®Google Scholar
• Kong X, Sun R, Chen Y, Wei H, Tian Z. gammadeltaT cells drive myeloid-derived suppressor cell-mediated CD8+ T cell exhaustion in hepatitis B virus-induced immunotolerance. J Immunol 2014; 193:1645-53; https://doi.org/10.4049/jimmunol.1303432
   PubMed Web of Science ®Google Scholar
• Maini MK, Gehring AJ. The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol 2016; 64:S60-70; PMID:27084038; https://doi.org/10.1016/j.jhep.2016.01.028
   PubMed Web of Science ®Google Scholar
• Peppa D, Gill US, Reynolds G, Easom NJ, Pallett LJ, Schurich A, Micco L, Nebbia G, Singh HD, Adams DH, et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med 2013; 210:99-114; PMID:23254287; https://doi.org/10.1084/jem.20121172
   PubMed Web of Science ®Google Scholar
• Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, Dunn C, Pallant C, Ellis G, Khanna P, Dusheiko G, et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathogens 2010; 6:e1001227; PMID:21187913; https://doi.org/10.1371/journal.ppat.1001227
   PubMed Web of Science ®Google Scholar
• Huan SL, Zhao JG, Wang ZL, Gao S, Wang K. Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infection. BMC Infectious Dis 2016; 16:200; PMID:27180842; https://doi.org/10.1186/s12879-016-1543-x
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cobleigh MA, Lian JQ, Huang CX, Booth CJ, Bai XF, Robek MD. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology 2011; 141:1897-906; PMID:21708106; https://doi.org/10.1053/j.gastro.2011.06.051
   PubMed Web of Science ®Google Scholar
• Moreno-Cubero E, Larrubia JR. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol 2016; 22:6469-83; PMID:27605882; https://doi.org/10.3748/wjg.v22.i28.6469
   PubMed Web of Science ®Google Scholar
• Akbar SM, Al-Mahtab M, Khan MS, Raihan R, Shrestha A. Immune therapy for hepatitis B. Annals Translational Med 2016; 4:335; PMID:27761439; https://doi.org/10.21037/atm.2016.08.48
   PubMed Web of Science ®Google Scholar
• Wen YM, Wu XH, Hu DC, Zhang QP, Guo SQ. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 1995; 345:1575-6; PMID:7791465; https://doi.org/10.1016/S0140-6736(95)91126-X
   PubMed Web of Science ®Google Scholar
• Zheng BJ, Ng MH, He LF, Yao X, Chan KW, Yuen KY, Wen YM. Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice. Vaccine 2001; 19:4219-25; PMID:11457548; https://doi.org/10.1016/S0264-410X(01)00158-X
   PubMed Web of Science ®Google Scholar
• Zheng BJ, Zhou J, Qu D, Siu KL, Lam TW, Lo HY, Lee SS, Wen YM. Selective functional deficit in dendritic cell–T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J Viral Hepatitis 2004; 11:217-24; PMID:15117323; https://doi.org/10.1111/j.1365-2893.2004.00497.x
   PubMed Web of Science ®Google Scholar
• Liu H, Geng S, Wang B, Wu B, Xie X, Wang S, Zhong Y, Wang X, Qu D, Wen Y, et al. Immuno-potentiating pathway of HBsAg-HBIG immunogenic complex visualized. Hum Vaccines Immunotherapeutics 2016; 12:77-84; https://doi.org/10.1080/21645515.2015.1072660
   PubMed Web of Science ®Google Scholar
• Xu DZ, Huang KL, Zhao K, Xu LF, Shi N, Yuan ZH, Wen YM. Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine 2005; 23:2658-64; PMID:15780449; https://doi.org/10.1016/j.vaccine.2004.10.040
   PubMed Web of Science ®Google Scholar
• Xu DZ, Zhao K, Guo LM, Li LJ, Xie Q, Ren H, Zhang JM, Xu M, Wang HF, Huang WX, et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PloS One 2008; 3:e2565; PMID:18596958; https://doi.org/10.1371/journal.pone.0002565
   PubMed Web of Science ®Google Scholar
• Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 2013; 59:450-6; PMID:23669281; https://doi.org/10.1016/j.jhep.2013.05.003
   PubMed Web of Science ®Google Scholar
• Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, Janssen HL. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41:771-8; PMID:15791617; https://doi.org/10.1002/hep.20649
   PubMed Web of Science ®Google Scholar
• Kakimi K, Isogawa M, Chung J, Sette A, Chisari FV. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J Virol 2002; 76:8609-20; PMID:12163580; https://doi.org/10.1128/JVI.76.17.8609-8620.2002
   PubMed Web of Science ®Google Scholar
• Han Q, Lan P, Zhang J, Zhang C, Tian Z. Reversal of hepatitis B virus-induced systemic immune tolerance by intrinsic innate immune stimulation. J Gastroenterol Hepatol 2013; 28 Suppl 1:132-7; PMID:23855309; https://doi.org/10.1111/jgh.12034
   PubMed Web of Science ®Google Scholar
• Carey I, D'Antiga L, Bansal S, Longhi MS, Ma Y, Mesa IR, Mieli-Vergani G, Vergani D. Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy. J Virol 2011; 85:2416-28; PMID:21147914; https://doi.org/10.1128/JVI.01449-10
   PubMed Web of Science ®Google Scholar
• Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Therapeutics 2013; 138:452-69; https://doi.org/10.1016/j.pharmthera.2013.03.004
   PubMed Web of Science ®Google Scholar
• Rini B. Future approaches in immunotherapy. Seminars Oncol 2014; 41 Suppl 5:S30-40; PMID:25438998; https://doi.org/10.1053/j.seminoncol.2014.09.005
   PubMed Web of Science ®Google Scholar
• Yang FQ, Yu YY, Wang GQ, Chen J, Li JH, Li YQ, Rao GR, Mo GY, Luo XR, Chen GM. A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepatitis 2012; 19:581-93; PMID:22762143; https://doi.org/10.1111/j.1365-2893.2012.01589.x
   PubMed Web of Science ®Google Scholar
• Yao X, Zheng B, Zhou J, Xu DZ, Zhao K, Sun SH, Yuan ZH, Wen YM. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 2007; 25:1771-9; PMID:17224217; https://doi.org/10.1016/j.vaccine.2006.11.019
   PubMed Web of Science ®Google Scholar
• Lok AS, Pan CQ, Han SH, Trinh HN, Fessel WJ, Rodell T, Massetto B, Lin L, Gaggar A, Subramanian GM, et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol 2016; 65:509-16; PMID:27210427; https://doi.org/10.1016/j.jhep.2016.05.016
   PubMed Web of Science ®Google Scholar
• Lobaina Y, Aguiar J, Penton E, Guillen G, Mahtab M, Uddin H, Raihan R, Akbar F, Pujol F, Loureiro CL, Aguilar JC. Demonstration of safety, immunogenicity and evidences of efficacy of the therapeutic vaccine candidate HeberNasvac and characterization of chronic hepatitis B patient populations. Biotecnologia Aplicada 2015; 32:3511-13.
   Google Scholar
• Al-Mahtab M, Bazinet M, Vaillant A. Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection. PloS One 2016; 11:e0156667; PMID:27257978; https://doi.org/10.1371/journal.pone.0156667
   PubMed Web of Science ®Google Scholar
• Godon O, Evlachev A, Bourgine M, Meritet JF, Martin P, Inchauspe G, Michel ML. Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes. Vaccine 2015; 33:4548-53; PMID:26209840; https://doi.org/10.1016/j.vaccine.2015.07.020
   PubMed Web of Science ®Google Scholar